call beat expand payer
access industri headwind remain
improv visibl bumpi road like still ahead
earlier today publish first look result link
addit takeaway confer call overal result reflect
combin expect volume benefit unh/aet contract chang volume
growth carri acquisit improv hospit refer test volume
favor weather impact partial off-set continu price pressur
higher patient concess one fewer sell day impact volume
margin management continu frame price headwind
spread rel evenli beyond multipl factor discuss
test mix could also skew revenu per requisit rest due faster esoter
test growth off-set lower rev/req point-of-servic po busi
magnitud factor key variabl model management also call sever
one-off factor impact rest includ neg impact
passov extra sell day solid yoy growth due softer comp
expand access prefer statu take time play
track anticip share gain expect volum build
span across quarter dgx unchang full-year guid includ
signific volum gain unh prefer lab network pln given time effort
need educ physician still await pln full detail expect
volum benefit management highlight includ pln
suggest addit price step-down talk sever nation
payer similar set-up howev take time share gain competit
dynam industri consolid theme play
adjust estim sale rais po
model sale adj ep estimate
better visibl higher sale margin assumpt rais po
base ev/ebitda estimate although believ
nation lab eventu benefit on-going lab industri turmoil
remain cautiou given uncertainti reiter under-perform rate
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
largest provid clinic diagnost
test relat servic deliv
nation network full-servic clinic
laboratori patient servic center
clinic lab oper highli competit
price-deflationari environ although
long-term see upsid potenti
elev lab consolid catalyz medicar
opportun monet lab data recent
multipl guidanc cut suggest visibl
limit see potenti
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
price object base ev/ebitda multipl
line compani median two year forward multipl last ten
year given recent soft volum trend lack full understand root
caus weak believ still potenti downsid risk addit
upsid risk faster expect materi hospit lab consolid
trend margin expans due higher specialti test mix faster volum growth
consum genom trend
downsid risk greater expect price headwind lower expect test
volum growth competit execut risk integr risk data privaci risk
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
